These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 7374693)
1. FDA's classification of new drugs. Schneiweiss F N Engl J Med; 1980 Jun; 302(24):1368-9. PubMed ID: 7374693 [No Abstract] [Full Text] [Related]
2. The FDA's classification system for new drugs. An evaluation of therapeutic gain. Finkel MJ N Engl J Med; 1980 Jan; 302(3):181-3. PubMed ID: 7350458 [No Abstract] [Full Text] [Related]
3. Understanding the FDA's guarded system for classifying new drugs. Schneiweiss F Hosp Pharm; 1979 May; 14(5):262-4, 266, 268 passim. PubMed ID: 10316828 [No Abstract] [Full Text] [Related]
4. The FDA's new drug rating system. Ohio Med; 1991 Mar; 87(3):133-4. PubMed ID: 2030884 [No Abstract] [Full Text] [Related]
5. Linking a policy on nonformulary drugs to the FDA's therapeutic-potential classification system. Poirier TI; Vorbach M; Bache T Am J Hosp Pharm; 1994 Sep; 51(18):2277-8. PubMed ID: 7801989 [No Abstract] [Full Text] [Related]
6. The FDA's response to AIDS: paradigm shift in new drug policy? Podraza R Food Drug Law J; 1993; 48(3):351-75. PubMed ID: 11653267 [No Abstract] [Full Text] [Related]
8. Upon closer inspection. As the U.S. imports more drugs and devices, the FDA's overseas initiatives aim to head off trouble at the source. Rhea S Mod Healthc; 2009 Mar; 39(13):28-30. PubMed ID: 19405431 [No Abstract] [Full Text] [Related]
9. PDA's response to FDA's "Guideline on sterile drug products produced by aseptic processing". Akers JE; Agalloco JP; Carleton FJ; Korczynski MS J Parenter Sci Technol; 1988; 42(4):114-7. PubMed ID: 3183865 [No Abstract] [Full Text] [Related]
11. When is a medical product too risky? An interview with FDA's top drug official. Interview by Tamar Nordenberg. Woodcock J FDA Consum; 1999; 33(5):8-11, 13. PubMed ID: 10522164 [No Abstract] [Full Text] [Related]
12. Old, new, and not new drugs. Knobloch CP J Am Vet Med Assoc; 1979 Oct; 175(7):698. PubMed ID: 528312 [No Abstract] [Full Text] [Related]
13. FDA's regulation of prescription drug labeling: a role for implied preemption. Kendrick LC Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031 [No Abstract] [Full Text] [Related]
14. FDA's new rule on treatment use and sale of investigational new drugs. Levine RJ IRB; 1987; 9(4):1-4. PubMed ID: 11649946 [No Abstract] [Full Text] [Related]
15. FDA's safety reform is greeted with scepticism. Moynihan R BMJ; 2005 Feb; 330(7489):435. PubMed ID: 15731128 [No Abstract] [Full Text] [Related]
16. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate. Dorfman HL; Quinn VM; Brophy EA Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765 [No Abstract] [Full Text] [Related]
17. The FDA's enforcement of IRBs and patient informed consent. Kelsey FO Food Drug Cosmet Law J; 1989 Jan; 44(1):13-20. PubMed ID: 11651627 [No Abstract] [Full Text] [Related]
18. Can (or should) the IRB assume the FDA's functions at early stages of the IND process? Levine RJ IRB; 1981 Dec; 3(10):4-5. PubMed ID: 11649414 [No Abstract] [Full Text] [Related]
19. Promoting public health and protecting consumers in a global economy: an overview of HHS/FDA's international activities. Kelly DP; Bachorik LL Food Drug Law J; 2005; 60(3):339-46. PubMed ID: 16304741 [No Abstract] [Full Text] [Related]
20. FDA's policy statement for the development of new stereoisomeric drugs. Chirality; 1992; 4(5):338-40. PubMed ID: 1354468 [No Abstract] [Full Text] [Related] [Next] [New Search]